Co-Founder, CFO and COO
Mark Bagnall co-founded Naia Limited and currently serves as chief financial officer, chief operating officer and a director.
He has held senior management positions in public and private biotechnology companies for more than 20 years. During that time he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings, and negotiated numerous licensing agreements.
Prior to founding Naia, he served as president, chief executive officer and a member of the Board of Directors of GenturaDx until its successful sale to Luminex Corporation. GenturaDx was a BVI-based molecular diagnostics company with operations in Shanghai, China and the San Francisco Bay Area. Before joining GenturaDx, Mr Bagnall was executive vice president and a member of the Board of ADVENTRX Pharmaceuticals. Prior to ADVENTRX, he was senior vice president at Metabolex, Inc., where he raised more than $100 million Before Metabolex, Mr Bagnall was chief financial officer of several public and private biotechnology companies and was responsible for many public and private financings, mergers and licensing transactions.
Mr Bagnall was one of the founders the Association of Bioscience Financial Officers, an international organization of life science CFOs. He serves on the Board of Directors of Ativa Medical Corporation is an advisor to the Board of Fluoresentric, Inc. Previously, he served on the Boards of ADVENTRX Pharmaceuticals and VIA Pharmaceuticals. He is a CPA and started his career in the high technology/biotechnology practice of Ernst & Young.